Skip to main content
OpenTrials
Recruiting

NCT Number: NCT01851642

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their ability to work.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

AAT deficiency is a genetic disorder that affects around 100,000 people in the USA, including 1-3% of all people diagnosed with chronic obstructive pulmonary disease (COPD). In AAT deficient people diagnosed with COPD, it was originally believed the cause of the disease was due to a lack of supply of alpha-1 antitrypsin. However, early information gathered in our laboratory suggests another cause of the development of COPD and the progressing of the disease may be due to a malfunction in macrophages.

CF is also a genetic disorder which affects 1/300 births among the Caucasian population. One of the main symptoms of CF is inflammation of the lung tissue. Lung macrophages play a major role in lung inflammation as well as in helping to resolve the inflammation.

Inflammation is an important defense of the body. It is the body's response to infection causing germs and things that may cause irritation, as well as, a way for the body to repair damaged tissue.

We suggest that the effects of AAT deficiency and CF decreases the inflammation response in the lungs and also restricts the ability of macrophages to correct that inflammation once it occurs.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent
  • Male or female 18 years of age or older
  • Negative pregnancy test for women of childbearing potential
  • Hemoglobin >12.5 g/dl measured on the day of participation
  • Negative urine nicotine test

Exclusion criteria

  • Pregnancy or breastfeeding
  • Weight < 50 kg
  • History of anemia requiring blood transfusions, erythropoietin supplementation, or iron supplementation within the past 36 months
  • Known hemoglobin <12.5 g/dl within the past 90 days
  • Systolic blood pressure > 180 mmHg and/or diastolic blood pressure >100 mmHg
  • Poor venous access
  • Large volume blood donation (>200 ml or 7 ounces) within the previous 56 days (e.g. blood donation for the purposes of blood banking)
  • Clinically significant cardiac, hemostatic or neurological impairment or any other significant medical condition that, in the opinion of the investigator would affect subject safety (e.g., recent myocardial infarction, history of prolonged bleeding time, cerebral vascular accident, advanced cancer or uncontrolled medical condition)
  • Psychiatric or cognitive disturbance or illness that would affect subject safety
  • Current smoker

Treatment and study plan

History and physical exam.

Procedure

At every study visit, participant's will be asked about their medical history and will have a physical exam.

Other names: H&P

Blood draw.

Procedure

At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.

Other names: Phlebotomy

Pulmonary function testing.

Procedure

At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.

Other names: PFTs

Albuterol inhaler.

Drug

At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.

Other names: Ventolin, Proventil, Proventil-HFA, AccuNeb, Vospire, ProAir

Primary outcomes

  1. Evaluation of macrophage function.

    Time frame: On average, within 30 days from the time the blood is collected.

    From every study participant, we will collect blood from a vein through the placement of an intravenous catheter (IV). We will complete various experiments that will allow us to see how well each participant's macrophage cells are working.

Secondary outcomes

  1. Comparison of the amount of alpha-1 antitrypsin in the blood.

    Time frame: On average, within 30 days from the time the blood was collected.

    From every study participant, we will collect blood from a vein through an IV.

  2. Comparison of the amount of an inflammatory marker in the blood, called C-reactive protein.

    Time frame: On average, within 30 days from the time the blood is collected.

    From every study participant, we will collect blood from a vein through and IV.

  3. Evaluation of lung function.

    Time frame: On average, within 30 days from the time the testing is completed.

    Lung function testing will be done on every study participant. This is is done by forcefully blowing into a tube on at least 3 separate occasions. Albuterol, an inhaled medication used to expand lung airways, will be given after lung function testing and then the testing will be repeated after 30 minutes.

Study contacts

Contact information is provided by the study sponsor or research team.

Allison E. Faunce, B.A.

CONTACT

[email protected]

352-273-8666

Michelle Owens, RN, BSN

CONTACT

[email protected]

352-273-6339

Sponsors and collaborators

Lead sponsor

University of Florida

Other

Registry information

Official study title

The Role of Conformational Diseases on Macrophage Function

Important dates

Study start
2007
Primary completion
2032
Study completion
2033
First posted
May 10, 2013
Registry last updated
Nov 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.